Translate this page to:
In JoVE (1)
Other Publications (8)
This translation into Turkish was automatically generated.
English Version | Other Languages
Articles by John Saksa in JoVE
Gerçek zamanlı fMRI Biofeedback Kirlilik Anksiyete orbitofrontal korteks Hedefleme
Michelle Hampson1, Teodora Stoica1, John Saksa2, Dustin Scheinost1, Maolin Qiu1, Jitendra Bhawnani1, Christopher Pittenger2,3,4, Xenophon Papademetris1, Todd Constable1
1Department of Diagnostic Radiology, Yale University School of Medicine, 2Department of Psychiatry, Yale University School of Medicine, 3Yale Child Study Center, Yale University School of Medicine, 4Interdepartmental Neuroscience Program, Yale University School of Medicine
Burada kirlenme anksiyete katılan bir beyin alanı kontrol etmek için eğitim insanlar için ve kirlenme anksiyete ve beyin bağlantısı desenler arasındaki ilişkiyi problama için bir yöntem sunuyoruz.
Other articles by John Saksa on PubMed
Mood-stabilizer-maintained, Remitted Bipolar Patients: Taper and Discontinuation of Adjunctive Antipsychotic Medication
General Hospital Psychiatry. May-Jun, 2004 | Pubmed ID: 15121352
The aim of this study was to determine whether bipolar patients who had been stabilized on combined antipsychotic and mood-stabilizer medications and were currently in remission benefited from continuation of the antipsychotic medication. Remitted bipolar patients were randomly assigned to either remain on adjunctive antipsychotic medication or to taper to placebo. Antipsychotic/placebo medication assignment was double-blind. Subjects were outpatients at a university-affiliated community mental health center. Fifteen subjects consented and proceeded with eligibility assessments. Five subjects were never randomized. One of these was excluded when the Structured Clinical Interview for DSM-IV interview revealed schizoaffective disorder. The remaining four subjects were not randomized for other reasons. Three randomized subjects never received study medications, or were withdrawn by the investigator within 1 week after beginning study medications. The seven remaining subjects received study medication for more than 1 week. Five subjects were randomized to taper to placebo and two to antipsychotic continuation. Of the five randomized to taper to placebo, three successfully tapered and completed the year of follow-up in continuous remission. One subject became manic 4 months after taper was completed, and one subject became psychotic, in the absence of a mood episode, during taper. Of the two subjects randomized to double-blind antipsychotic continuation, both completed the year of follow-up in continuous remission. When adjunctive antipsychotic medications are discontinued, bipolar patients' clinical symptoms can remain unchanged. Others are, however, at risk for manic relapse.
Biological Psychiatry. Sep, 2005 | Pubmed ID: 15993857
Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.
Predictors and Time Course of Response Among Panic Disorder Patients Treated with Cognitive-behavioral Therapy
The Journal of Clinical Psychiatry. Mar, 2008 | Pubmed ID: 18278989
Cognitive-behavioral therapy (CBT) is well documented as an efficacious treatment for panic disorder. We provided open CBT treatment to patients who subsequently participated in a maintenance treatment study. This article reports on predictors and trajectory of response in 381 participants who completed treatment at 4 sites.
Effects of Levetiracetam on Tardive Dyskinesia: a Randomized, Double-blind, Placebo-controlled Study
The Journal of Clinical Psychiatry. Apr, 2008 | Pubmed ID: 18312060
The goal of this study was to evaluate the efficacy and safety of levetiracetam versus placebo for tardive dyskinesia (TD).
Cognitive Behavior Therapy for Early Psychosis: a Comprehensive Review of Individual Vs. Group Treatment Studies
International Journal of Group Psychotherapy. Jul, 2009 | Pubmed ID: 19548785
Several recent studies of individually administered cognitive behavior therapy (CBT) for early psychosis have reported only modest treatment benefits. The purpose of the current study was to review the literature to determine how outcomes of group CBT differ from outcomes of individually administered CBT among early cases. Our findings suggest that group CBT for early psychosis may be a more effective modality for this group of patients. We speculate that patients' uncertainty about illness in general may impair the effectiveness of individually administered CBT for early cases and that group CBT may be more effective for these young patients by better addressing those factors with the aid of peer-to-peer interactions, identification, and modeling.
Incidence of Tardive Dyskinesia with Atypical Versus Conventional Antipsychotic Medications: a Prospective Cohort Study
The Journal of Clinical Psychiatry. Apr, 2010 | Pubmed ID: 20156410
Most previous studies of the incidence of tardive dyskinesia with atypical antipsychotics compared with conventional antipsychotics have not had tardive dyskinesia as their primary focus. The current study aimed to compare the incidence of tardive dyskinesia with atypical vs conventional antipsychotics using methods similar to those from a previous prospective cohort study at our site in the 1980s.
Schizophrenia Research. Aug, 2010 | Pubmed ID: 20541910
D-serine is an allosteric modulator of the brain N-methyl-d-aspartate (NMDA) receptor and a potential novel treatment of schizophrenia. Double-blind studies have been performed at 30 mg/kg/day (approximately 2 g/day) with encouraging results, but no formal dose escalation studies have been performed. We describe the first evaluation of the efficacy and safety of d-serine at doses >30 mg/kg/day; a 4-week, open-label trial of adjunctive D-serine (30, 60 or 120 mg/kg/day).
Schizophrenia Research. Nov, 2010 | Pubmed ID: 20832249
The American Psychiatric Association Task Force on DSM-5 has recently proposed consideration of Attenuated Psychotic Symptoms Syndrome as a new diagnosis, based on nearly 15 years of prospective research in centers across the globe. The condition is also known as "psychosis risk syndrome," "at-risk mental state," "ultra-high risk," and "putative prodrome." We review evidence favoring its inclusion as a new diagnosis in DSM-5 and report new preliminary findings on DSM-IV diagnoses in current clinical use for these patients and on results of diagnostic interviews in unselected volunteers. The main evidence supporting inclusion is: (1) the patients are currently ill, (2) the patients are at high risk for getting worse, (3) no DSM-IV diagnosis accurately captures their current illness or future risk, (4) the diagnosis has been made with reliability and validity in the research setting, and (5) placement in DSM-5 would help promote the needed treatment and prevention research to enable articulation of a standard of care to benefit these patients and their families. Potential harms can be minimized by patient, family, and provider education. It will be important to demonstrate through well-designed field trials whether the diagnostic criteria can be used with reliability in everyday clinical practice.